WO2009010810A3 - Associations cardiovasculaires comprenant des inhibiteurs de l'ace et de l'hmg-co-a - Google Patents

Associations cardiovasculaires comprenant des inhibiteurs de l'ace et de l'hmg-co-a Download PDF

Info

Publication number
WO2009010810A3
WO2009010810A3 PCT/IB2006/002614 IB2006002614W WO2009010810A3 WO 2009010810 A3 WO2009010810 A3 WO 2009010810A3 IB 2006002614 W IB2006002614 W IB 2006002614W WO 2009010810 A3 WO2009010810 A3 WO 2009010810A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
hmg
cardiovascular
ace
combinations
Prior art date
Application number
PCT/IB2006/002614
Other languages
English (en)
Other versions
WO2009010810A2 (fr
Inventor
Eswaran Krishnan Iyer
Rasendra Kumar Jayantilal Jha
Girish Kumar Jain
Abdul Rehman Khan
Original Assignee
Wockhardt Ltd
Eswaran Krishnan Iyer
Rasendra Kumar Jayantilal Jha
Girish Kumar Jain
Abdul Rehman Khan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd, Eswaran Krishnan Iyer, Rasendra Kumar Jayantilal Jha, Girish Kumar Jain, Abdul Rehman Khan filed Critical Wockhardt Ltd
Priority to PCT/IB2006/002614 priority Critical patent/WO2009010810A2/fr
Publication of WO2009010810A2 publication Critical patent/WO2009010810A2/fr
Publication of WO2009010810A3 publication Critical patent/WO2009010810A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention décrit de nouvelles compositions pharmaceutiques, leur procédé de fabrication et l'utilisation de ces compositions à administrer sous forme d'association thérapeutique pour le traitement de troubles cardiovasculaires et apparentés, en particulier une association d'inhibiteurs de l'ACE ou de bloqueurs des canaux calciques, de régulateurs lipidiques (inhibiteurs de l'HMG-Co-A) et d'inhibiteurs de l'agrégation plaquettaire.
PCT/IB2006/002614 2006-08-07 2006-08-07 Associations cardiovasculaires comprenant des inhibiteurs de l'ace et de l'hmg-co-a WO2009010810A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/002614 WO2009010810A2 (fr) 2006-08-07 2006-08-07 Associations cardiovasculaires comprenant des inhibiteurs de l'ace et de l'hmg-co-a

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/002614 WO2009010810A2 (fr) 2006-08-07 2006-08-07 Associations cardiovasculaires comprenant des inhibiteurs de l'ace et de l'hmg-co-a

Publications (2)

Publication Number Publication Date
WO2009010810A2 WO2009010810A2 (fr) 2009-01-22
WO2009010810A3 true WO2009010810A3 (fr) 2009-04-16

Family

ID=40260141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002614 WO2009010810A2 (fr) 2006-08-07 2006-08-07 Associations cardiovasculaires comprenant des inhibiteurs de l'ace et de l'hmg-co-a

Country Status (1)

Country Link
WO (1) WO2009010810A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023869A1 (fr) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. PRÉPARATION PHARMACEUTIQUE COMBINÉE À LIBÉRATION CONTRÔLÉE COMPRENANT DES INHIBITEURS CALCIQUES À BASE DE DIHYDROPYRIDINE ET DES INHIBITEURS DE HMG-CoA RÉDUCTASE
WO2010103384A1 (fr) * 2009-03-13 2010-09-16 Nucitec S.A. De C.V. Compositions et méthodes de traitement et prévention de maladies cardiovasculaires
EP2340814A3 (fr) * 2009-12-31 2012-05-23 Ranbaxy Laboratories Limited Comprimé d'aspirine stable et son procédé de préparation
CA2800520A1 (fr) 2010-04-08 2011-10-13 The Hospital For Sick Children Utilisation du conditionnement ischemique a distance pour une lesion traumatique
WO2014167423A2 (fr) 2013-03-15 2014-10-16 The Hospital For Sick Children Procédés pour moduler une autophagie en utilisant un conditionnement ischémique à distance
US10098779B2 (en) 2013-03-15 2018-10-16 The Hospital For Sick Children Treatment of erectile dysfunction using remote ischemic conditioning
CA2904162A1 (fr) 2013-03-15 2014-12-18 The Hospital For Sick Children Methodes se rapportant a l'utilisation du conditionnement ischemique a distance
US11166939B2 (en) * 2017-04-25 2021-11-09 Otsuka Pharmaceutical Co. Ltd Lisinopril compositions with an ingestible event marker
CN108464972A (zh) * 2018-07-02 2018-08-31 福州大学 一种含有斯诺普利的抗肺动脉高压口服片剂及其制备方法
CN113081996A (zh) * 2021-04-01 2021-07-09 海南锦瑞制药有限公司 一种辛伐他汀胶囊的制备方法和辛伐他汀胶囊

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022890A1 (en) * 1999-12-06 2003-01-30 Atwal Karnail S. Heterocyclic dihydropyrimidine compounds
US20040022844A1 (en) * 2001-10-30 2004-02-05 Steffen Hasenzahl Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US20040110793A1 (en) * 2002-04-19 2004-06-10 John Lloyd Heterocyclo inhibitors of potassium channel function

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022890A1 (en) * 1999-12-06 2003-01-30 Atwal Karnail S. Heterocyclic dihydropyrimidine compounds
US20040022844A1 (en) * 2001-10-30 2004-02-05 Steffen Hasenzahl Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US20040110793A1 (en) * 2002-04-19 2004-06-10 John Lloyd Heterocyclo inhibitors of potassium channel function

Also Published As

Publication number Publication date
WO2009010810A2 (fr) 2009-01-22

Similar Documents

Publication Publication Date Title
WO2009010810A3 (fr) Associations cardiovasculaires comprenant des inhibiteurs de l'ace et de l'hmg-co-a
WO2010127099A3 (fr) Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
WO2012075383A3 (fr) Inhibiteurs de bromodomaines et leurs utilisations
WO2012174487A8 (fr) Inhibiteurs à bromodomaine et leurs utilisations
WO2012151512A3 (fr) Inhibiteurs de bromodomaines et leurs utilisations
WO2008115974A3 (fr) Analogues de pyrazolopyrimidine et leur utilisation en tant qu'inhibiteurs de kinase mtor et kinase pi3
WO2007127505A3 (fr) Composés chimiques
WO2012080727A3 (fr) Inhibiteurs de caséine kinase 1 delta (ck1delta)
EP2129683A4 (fr) Procedes et compositions pour le traitement de l'insuffisance cardiaque et d'autres troubles
HK1146485A1 (fr)
WO2009036175A3 (fr) Inhibiteur de f1f0-atpase et procédés associés
WO2012154679A8 (fr) Composés de sulfonamide pyrazole tricycliques et leurs procédés de fabrication et d'utilisation
WO2009153665A3 (fr) Inhibiteurs des toxines shiga circulant dans la voie de transport rétrograde
WO2009121039A3 (fr) Administration de compositions de benzodiazépine
WO2007082068A3 (fr) Procedes et compositions pour le traitement de l’asthme chez les primates humains et non humains
WO2009121872A3 (fr) Tétrahydroisoquinoléines, compositions pharmaceutiques les contenant et leur utilisation en thérapie
WO2007143607A3 (fr) Procédé de traitement de la vaginite atrophique
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
HK1129426A1 (zh) 用於治療肺部病症的酶的合成物
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
WO2012135619A3 (fr) Compositions pharmaceutiques intranasales de benzodiazépine
WO2009035634A3 (fr) Cyanoaminoquinolones et tétrazoloaminoquinolones en tant qu'inhibiteurs de gsk-3
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06795533

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06795533

Country of ref document: EP

Kind code of ref document: A2